Form Type: 4

SEC EDGAR Link
Accession Number:0001127602-19-034363
Date:2019-12-03
Issuer: BIOGEN INC. (BIIB)
Original Submission Date:

Reporting Person:

KRAMER ROBIN
225 BINNEY STREET
CAMBRIDGE, MA 02142

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-12-03 M 84 a $0.00 175 direct
COMMON STOCK 2019-12-03 F 25 d $290.70 150 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
RESTRICTED STOCK UNIT 0.0 2019-12-03 deemed execution date M 84 (d) 2021-12-03 common stock 84 $0.00 446 direct
RESTRICTED STOCK UNIT 0.0 2019-12-03 deemed execution date J 92 (d) 2021-12-03 common stock 92 $0.00 354 direct
Footnotes
IDfootnote
f1 includes 51.685 shares acquired under the biogen inc. employee stock purchase plan on 3/29/2019.
f2 includes 39.796 shares acquired under the biogen inc. employee stock purchase plan on 6/28/2019.
f3 the number of rsus reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. one-third of these rsus are eligible to vest on each of the first three anniversaries of the grant date. the actual number of shares that will vest on each vesting date will be determined by comparing the price of biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
f4 this represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
WhaleWisdom Logo

Elevate your investments